| Document |
Document Title |
|
WO/2023/238916A1 |
The present invention addresses the problem of providing hollow spherical particles that have superior safety and can be produced more easily. This problem is solved by hollow spherical particles which are self-assembled bodies of a lign...
|
|
WO/2023/237542A1 |
Exacerbation of heart failure, better known as acute decompensated heart failure (HF), is characterized by dyspnea, edema and fatigue, and is a growing medical problem. The inventors demonstrated that transient O-GlcNAcase inhibition wou...
|
|
WO/2023/237067A1 |
The use of Akkermansia muciniphila or a composition containing Akkermansia muciniphila in preparation of a pharmaceutical composition or a health care product composition for improving metabolic syndrome. The Akkermansia muciniphila is A...
|
|
WO/2023/240258A1 |
The present invention provides methods of treating B-cell disorders with combination therapies comprising the use of (i) a targeted B-cell therapy; (ii) an IL-6 modulator, and (iii) a CXCR4 inhibitor; or (i) a targeted B-cell therapy and...
|
|
WO/2023/239908A1 |
The present invention relates to a method of treating a mitochondrial disease in a patient in need thereof by administering Compound (I), a stimulator of soluble guanylate cyclase (sGC) at certain dosages either alone or in combination t...
|
|
WO/2023/236976A1 |
A lipid compound and a preparation method therefor, and a use thereof. The lipid compound is safe, efficient and ionizable, and the structure of the lipid compound is divided into a hydrophilic amino group, a linking group, and a hydroph...
|
|
WO/2023/237060A1 |
The present invention relates to the field of biomedical macromolecular materials, and particularly, to an amphiphilic block polymer, a chemoradiotherapy nano sensitizer, and a method for preparing same. By means of chemical modification...
|
|
WO/2023/238939A1 |
Provided is a prophylactic or therapeutic which is against the exacerbation or recurrence of cancer due to cells including cancer stem cell that are in a dormant state during chemotherapy, and which has a YAP inhibitor as an active ingre...
|
|
WO/2023/240105A1 |
Described herein are hydrophobic compositions including a hydrophilic active ingredient and to methods of making and using the same.
|
|
WO/2023/237783A1 |
The present invention relates to the use of neocuproine, elesclomol, disulfiram and/or dithiocarbamate for use in treatment of cancer, optionally in combination with MAPK-pathway inhibitors in cancers carrying mutations that are recogniz...
|
|
WO/2023/233357A1 |
The disclosure relates to a subcutaneous dosage of Compound (I), or a pharmaceutically acceptable salt thereof, for the treatment of diseases or disorders mediated by negative allosteric modulation or inhibition of NR2B-containing NMDA r...
|
|
WO/2023/231780A1 |
Use of the CREPT gene or an expression product thereof as a target in the preparation of a drug for treating prostate cancer, use of a reagent targeting the CREPT gene or the expression product thereof in the preparation of a drug for tr...
|
|
WO/2023/234427A1 |
Provided is a conjugate precursor for obtaining a more useful antitumor agent by further developing a conventional antibody-drug conjugate. Provided are: an antibody-multidrug conjugate precursor represented by general formula (I) (in th...
|
|
WO/2023/235292A1 |
The disclosure provides a device for sustained release of a therapeutic agent, comprising a capsule configured for implantation and having a reservoir; a nanoporous membrane with a plurality of pores; the therapeutic agent disposed withi...
|
|
WO/2023/233791A1 |
Provided are: an integrin activator that contains a substance that inhibits binding between a fibronectin and an immune inhibitory receptor LILRB4 as an active ingredient; and a therapeutic agent that contains a substance that inhibits b...
|
|
WO/2023/232643A1 |
The present invention relates to high-dose vitamin K2, in particular menaquinone-7 (MK- 7), for use in the treatment of coronary heart disease in high-risk subjects having a coronary artery calcification (CAC) score ≥400 (e.g. at the o...
|
|
WO/2023/234410A1 |
The present invention addresses the problem of providing: an inhibitory agent for myocardial cell death; and a prophylactic or therapeutic agent for myocardial disorders or heart failure. The problem is solved by an inhibitory agent for ...
|
|
WO/2023/235380A1 |
Provided are 13 -membered ribosome targeting compounds that can be used to treat genetic diseases, including genetic diseases that are associated with a premature termination codon mutation or other nonsense mutation. The compounds can i...
|
|
WO/2023/234297A1 |
The present disclosure provides a composition that is for treating cancer and that contains at least one substance for breaking down a stem-loop structure in the 3'-untranslated region of Nfkbiz mRNA. Said stem-loop structure is at least...
|
|
WO/2023/232838A1 |
The present invention relates to a new use of bedaquiline.
|
|
WO/2023/232076A1 |
Cancer is a huge threat to human health, and no particularly good treatment method exists at present. The most important reason is that a very good method for specifically killing cancer cells with less impact on normal cells has not yet...
|
|
WO/2023/231086A1 |
The present invention relates to uses of DDUP for tumor drug resistance detection, for treatment, and as prognosis molecular targets. DDUP can regulate and control DNA damage and/or repair DNA damage, is remarkably related to the platinu...
|
|
WO/2023/233665A1 |
Provided are: an immunocyte activator containing, as an active ingredient, a substance which inhibits the binding of fibronectin and an immunosuppressive receptor LILRB4; and a therapeutic agent for immunocyte-related inflammatory diseas...
|
|
WO/2023/232752A1 |
The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effec...
|
|
WO/2023/234740A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cancer, containing, as an active ingredient, monocytes or macrophages in which the expression or activity of CD244 is inhibited. It has been identif...
|
|
WO/2023/232747A1 |
The present disclosure provides nucleic acid particles comprising an immunomodulator, RNA, and a cationic lipid or a cationic polymer, wherein nucleic acid particles described herein reduce inflammatory response and/or increase protein o...
|
|
WO/2023/235467A1 |
The present disclosure relates to methods for treating monkeypox infections. An exemplary method includes administering to a patient a therapeutically effective amount of a compound selected from adefovir, tenofovir, adefovir dipivoxil, ...
|
|
WO/2023/231942A1 |
The present application provides a pharmaceutical composition, comprising an anti-CLDN18.2 antibody-drug conjugate, a buffer, a stabilizer, and a surfactant. The present application further provides a method for preparing the pharmaceuti...
|
|
WO/2023/235553A1 |
Disclosed are methods of treating hemorrhagic shock, for example hemorrhagic shock associated with traumatic injury, gastrointestinal bleeding, spontaneous hemorrhage due to hematologic disorders, uterine hemorrhage, and combinations the...
|
|
WO/2023/232810A1 |
The present invention relates generally to the field of anti-cancer therapy and autoimmune therapy, in particular to the use of adoptive T cell transfer therapy. More specifically, the present invention relates to compositions, pharmaceu...
|
|
WO/2023/234250A1 |
The present invention provides a composition to be used for attenuating skin barrier, said composition containing an anionic long-chain lipid (in particular, a long-chain fatty acid). The present invention provides a dispersion in which ...
|
|
WO/2023/232958A1 |
The present invention relates to a method for treating suddenly occurring allergic reactions, such as acute allergic reactions, in a human through administration of a BTK inhibitor. In particular, the present invention relates to a metho...
|
|
WO/2023/234426A1 |
Provided is a more useful antitumor drug that is the result of further advancing conventional antibody-drug conjugates. An antibody-multidrug conjugate represented by general formula (I): [in the formula, the symbols have the meanings se...
|
|
WO/2023/232080A1 |
The present invention belongs to the field of biomedicine. Disclosed in the present invention are an anti-CLDN18.2 antibody, and an antibody-drug conjugate and use thereof. In some embodiments, the antibody-drug conjugate is a compound r...
|
|
WO/2023/235790A1 |
The present disclosure relates to recombinant polypeptides and uses thereof for treating, preventing, and detecting inflammatory diseases. Specifically, the disclosure provides a recombinant polypeptide comprising an IL-2 polypeptide, a ...
|
|
WO/2023/233362A1 |
A new use of estrogen-related receptor γ (ERRγ) inhibitor in enhancing cancer treatment and a pharmaceutical composition for inhibiting the resistance of cancer to tyrosine kinase inhibitors and enhancing an anticancer effect are discl...
|
|
WO/2023/235549A1 |
Disclosed are methods of treating sepsis in an individual in need thereof via administration of a therapeutically effective amount of a humanin protein, or an analog thereof, to the individual. In one aspect, the methods may comprise adm...
|
|
WO/2023/234346A1 |
The present invention addresses the problem of providing: a solid preparation obtained by blending an antacid and one or more types of compound selected from the group consisting of loxoprofen and a salt thereof, said preparation being a...
|
|
WO/2023/235490A1 |
Disclosed herein are methods of treating a subject for a condition associated with insufficient insulin secretion by administering to a subject in need of treatment for a condition associated with an insufficient level of insulin secreti...
|
|
WO/2023/230222A1 |
Methods for reducing the progression of ER+ breast cancer in a patient are provided, the methods comprising administering to the patient an effective amount of lasofoxifene or a pharmaceutically acceptable salt thereof and an effective a...
|
|
WO/2023/230593A1 |
Methods and compositions for treating lung injury include administering an effective amount of an PTP1B inhibitor to a subject in need thereof. The lung injury may, for example, be acute lung injury, antibody-induced acute lung, acute lu...
|
|
WO/2023/227081A1 |
Disclosed are a method for preventing cancer recurrence and inhibiting or reversing normal tissue inflammation and cancerization by inhibiting CREPT, use and a medicament. The present invention finds that the increase of CREPT expression...
|
|
WO/2023/225802A1 |
The present disclosure provides a trefoil factor 2 (TFF2)/interferon α2 (IFNα2) fusion protein and an application thereof in prevention and treatment of viral infectious diseases. Specifically, the present disclosure provides a fusion ...
|
|
WO/2023/227490A1 |
The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]
-pyrimidin-4-yl}-sulfamide: Formula (I) and its use as endothelin receptor antagonist in a method of treating hyperten...
|
|
WO/2023/227054A1 |
The present invention provides a compound and use thereof, particularly a JWA gene agonist and use thereof in preventing or treating radiation damage. The compound, by means of activating JWA gene expression, enhances the DNA repair capa...
|
|
WO/2023/230468A1 |
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
|
|
WO/2023/229013A1 |
Provided is a production method for proliferative myeloid cells that constitutively produce IL-12p70, the method comprising: (1) a step for introducing a nucleic acid encoding c-MYC into myeloid cells; (2) a step for culturing the cells ...
|
|
WO/2023/229032A1 |
Provided is a compound that exhibits anti-cancer activity based on CHK1 inhibition. The present disclosure is a result of the discovery that compounds represented by formula (1) or pharmacologically acceptable salts thereof have excellen...
|
|
WO/2023/229667A1 |
The present invention relates to compositions, systems, and methods for treating a subject with an eye condition (e.g., topically) using a composition comprising an ACE-2 receptor antagonist (also known as Angiotensin II Receptor Blocker...
|
|
WO/2023/228971A1 |
Provided is a novel preventative/therapeutic agent which is linked to the complete curing and treatment of IgA nephropathy. This IgA nephropathy preventative/therapeutic agent targets tonsillar indigenous bacteria derived from an anti-...
|
